EDUCATION

Undergraduate Degree

  • University of Michigan , 1991 , Ann Arbor , MI

Medical School

  • Kansas City University of Medicine and Biosciences , 1999 , Kansas City , MO

Internship

Internal Medicine and Pediatrics
  • Cleveland Clinic , Cleveland , OH

Residency

Internal Medicine and Pediatrics
  • Cleveland Clinic , Cleveland , OH

Fellowship

Pulmonary Medicine
  • Boston Children's Hospital , 2006 , Boston , MA

CERTIFICATIONS

  • American Board of Internal Medicine
  • American Board of Pediatrics, General Pediatrics

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Favorable Clinician Acceptability of Telehealth as Part of the Cystic Fibrosis Care Model during the COVID-19 Pandemic. Ann Am Thorac Soc. 2021 Feb 26. View abstract
  2. Men's health in the modern era of cystic fibrosis. J Cyst Fibros. 2020 Dec 26. View abstract
  3. The Effects of Ivacaftor on Bone Density and Microarchitecture in Children and Adults with Cystic Fibrosis. J Clin Endocrinol Metab. 2020 Dec 01. View abstract
  4. Integration of mental health screening and treatment into cystic fibrosis clinics: Evaluation of initial implementation in 84 programs across the United States. Pediatr Pulmonol. 2020 11; 55(11):2995-3004. View abstract
  5. Supporting the Medically Fragile: Individualized Approach to Empowering Young Adults With Chronic Disease During the COVID-19 Pandemic. J Adolesc Health. 2020 09; 67(3):453-455. View abstract
  6. Children's Hospitals Caring for Adults During a Pandemic: Pragmatic Considerations and Approaches. J Hosp Med. 2020 05; 15(5):311-313. View abstract
  7. Prevalence and clinical associations of Staphylococcus aureus small-colony variant respiratory infection in children with cystic fibrosis (SCVSA): a multicentre, observational study. Lancet Respir Med. 2019 12; 7(12):1027-1038. View abstract
  8. Antifibrinolytic Agents for Hemoptysis Management in Adults With Cystic Fibrosis. Chest. 2019 06; 155(6):1226-1233. View abstract
  9. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018 10 25; 379(17):1599-1611. View abstract
  10. Sexual and Reproductive Health of Young Women With Cystic Fibrosis: A Concept Mapping Study. Acad Pediatr. 2019 04; 19(3):307-314. View abstract
  11. A Pilot Study of Inspiratory Muscle Training to Improve Exercise Capacity in Patients with Fontan Physiology. Semin Thorac Cardiovasc Surg. 2018 Winter; 30(4):462-469. View abstract
  12. Overcoming barriers to a successful transition from pediatric to adult care. Pediatr Pulmonol. 2017 Nov; 52(S48):S52-S60. View abstract
  13. Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation. Clin Transl Gastroenterol. 2017 Mar 16; 8(3):e81. View abstract
  14. Comparison of Nasal Potential Difference and Intestinal Current Measurements as Surrogate Markers for CFTR Function. J Pediatr Gastroenterol Nutr. 2016 11; 63(5):e92-e97. View abstract
  15. Young adults with cystic fibrosis have altered trabecular microstructure by ITS-based morphological analysis. Osteoporos Int. 2016 08; 27(8):2497-505. View abstract
  16. Risk Factors for Hearing Loss in Patients with Cystic Fibrosis. J Am Acad Audiol. 2016 01; 27(1):6-12. View abstract
  17. Correlations of salivary biomarkers with clinical assessments in patients with cystic fibrosis. PLoS One. 2015; 10(8):e0135237. View abstract
  18. Trends in bone mineral density in young adults with cystic fibrosis over a 15 year period. J Cyst Fibros. 2015 Jul; 14(4):526-32. View abstract
  19. Compromised bone microarchitecture and estimated bone strength in young adults with cystic fibrosis. J Clin Endocrinol Metab. 2014 Sep; 99(9):3399-407. View abstract
  20. An automated integrated platform for rapid and sensitive multiplexed protein profiling using human saliva samples. Lab Chip. 2014 Mar 21; 14(6):1087-98. View abstract
  21. Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis. J Cyst Fibros. 2013 Jan; 12(1):54-9. View abstract
  22. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010 Nov 18; 363(21):1991-2003. View abstract
  23. Employment experiences among adolescents and young adults with cystic fibrosis. Disabil Rehabil. 2011; 33(11):922-6. View abstract
  24. A safe protocol for rapid desensitization in patients with cystic fibrosis and antibiotic hypersensitivity. J Cyst Fibros. 2009 Dec; 8(6):418-24. View abstract
  25. Sensorineural hearing loss in patients with cystic fibrosis. Otolaryngol Head Neck Surg. 2009 Jul; 141(1):86-90. View abstract
  26. Recovery of Herbaspirillum species from persons with cystic fibrosis. J Clin Microbiol. 2008 Aug; 46(8):2774-7. View abstract
  27. Airway epithelial control of Pseudomonas aeruginosa infection in cystic fibrosis. Trends Mol Med. 2008 Mar; 14(3):120-33. View abstract
  28. Polymerase chain reaction/denaturing gradient gel electrophoresis (PCR/DGGE): sensitivity, band pattern analysis, and methodologic optimization. Am J Dermatopathol. 1999 Dec; 21(6):547-51. View abstract
  29. High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex model. J Pharmacol Exp Ther. 1997 Feb; 280(2):576-83. View abstract
  30. 5-Hydroxytryptamine2A (5-HT2A) receptor desensitization can occur without down-regulation. J Pharmacol Exp Ther. 1995 Dec; 275(3):1638-46. View abstract
  31. Lymphomatoid papulosis and associated cutaneous lymphoproliferative disorders exhibit a common clonal origin. J Invest Dermatol. 1995 Jul; 105(1):51-5. View abstract
  32. Differential ergoline and ergopeptine binding to 5-hydroxytryptamine2A receptors: ergolines require an aromatic residue at position 340 for high affinity binding. Mol Pharmacol. 1995 Mar; 47(3):450-7. View abstract
  33. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar; 268(3):1403-10. View abstract